Compass Pathways Grant Program

The Compass U.S. Healthcare Provider Training Grant Program is administered by Compass Pathways, a biotechnology company focused on advancing evidence-based innovations in mental health treatment. The organization is actively developing COMP360, a synthetic psilocybin-based therapy intended for treatment-resistant depression, and this grant initiative is designed to support operational readiness in advance of a potential commercial launch in the United States. The program reflects Compass Pathways’ strategic priority to ensure that healthcare providers are adequately trained to deliver this therapy safely and effectively, should it receive regulatory approval. The primary purpose of this grant program is to fund the development of high-quality training content for healthcare providers. This includes both foundational psychedelic treatment education and specialized modules focused specifically on COMP360. The training is intended to prepare multidisciplinary teams of healthcare professionals to deliver care consistently and in alignment with expected regulatory and clinical standards. Compass Pathways aims to collaborate directly with selected organizations to co-develop these training materials, ensuring alignment with anticipated clinical and operational requirements across treatment sites. Funding through this program is expected to support up to three organizations that demonstrate strong capabilities in designing, delivering, and governing psychedelic treatment training. Eligible applicants must be able to create scalable training programs and demonstrate expertise in areas such as curriculum development, regulatory alignment, and inclusive access to care. The program emphasizes the importance of maintaining high standards in patient experience and care delivery, particularly in the context of emerging psychedelic therapies. The application process is structured in two stages. The initial application period opened on April 14, 2026 and will close on May 14, 2026. During the first stage, applicants are required to demonstrate their experience and operational capacity in developing and delivering training programs, particularly in the field of psychedelic care. Applicants are also expected to address considerations such as scalability, governance, and commitment to access and inclusion. Organizations that meet the initial criteria will be invited to proceed to the second stage of evaluation. Following submission, applicants can expect to receive notification regarding advancement to stage two by late May. The second stage will involve further evaluation and likely additional engagement with Compass Pathways. Final funding decisions are expected to be communicated by early July, with the overall evaluation process spanning approximately three months. Successful applicants will then collaborate with Compass Pathways to finalize and deploy training content aligned with the anticipated commercial rollout timeline. The grant program does not specify fixed funding amounts, award ranges, or matching requirements within the available materials. However, it clearly defines its strategic role in preparing the healthcare ecosystem for the potential introduction of COMP360 therapy. Contact information for inquiries is provided through designated media and investor relations representatives, and additional application details are accessible via the official application portal. This initiative represents a targeted investment in training infrastructure to support the responsible and scalable delivery of a novel mental health treatment in the United States.

Emphasize demonstrated experience in psychedelic training and ability to scale programs while aligning with regulatory expectations and inclusion priorities.